945 results on '"Schönland, Stefan"'
Search Results
152. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
153. In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography
154. Hereditary Apolipoprotein AI-Associated Amyloidosis in Surgical Pathology Specimens: Identification of Three Novel Mutations in the APOA1 Gene
155. Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study
156. A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis
157. Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21
158. Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study
159. Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda
160. Amyloid in endomyocardial biopsies
161. DUAL expectations in light chain amyloidosis
162. Three German fibrinogen Aα-chain amyloidosis patients with the p.Glu526Val mutation
163. Prognostic impact of early‐versus‐late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT
164. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis
165. Multiple myeloma gammopathies : Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance
166. Leitlinie : ICD10: E85.- : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen
167. Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic
168. Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience
169. Ruxolitinib is effective in the treatment of a patient with refractory T‐ALL
170. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data
171. Seeded fibrils of the germline variant of human λ-III immunoglobulin light chain FOR005 have a similar core as patient fibrils with reduced stability
172. Gain 1q21 Is an Adverse Prognostic Factor in Patients with Relapsed/Refractory AL Amyloidosis Treated with Lenalidomide and Dexamethasone
173. Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients
174. Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey
175. First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network
176. Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the Cmwp EBMT
177. Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis
178. Amyloidogenic core of a human λ-III immunoglobulin light chain fibril and their germline variants probed by MAS solid state NMR
179. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis
180. Modified body mass index and time interval between diagnosis and operation affect survival after liver transplantation for hereditary amyloidosis: a single-center analysis
181. Tissue biopsy for the diagnosis of amyloidosis: experience from some centres.
182. Submyeloablative total body irradiation‐based conditioning and allogeneic stem cell transplantation in high‐risk myeloma with early progression after up‐front autologous transplantation.
183. Solid state NMR assignments of a human λ-III immunoglobulin light chain amyloid fibril
184. Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression
185. Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT)
186. CT features in amyloidosis of the respiratory system – Comprehensive analysis in a tertiary referral center cohort
187. Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT
188. Allogeneic Transplantation in Multiple Myeloma—Does It Still Have a Place?
189. Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID‐19 pandemic
190. Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients
191. Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.
192. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria
193. Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis
194. Treosulfan conditioning for allogeneic transplantation in multiple myeloma – improved overall survival in first line haematopoietic stem cell transplantation – a large retrospective study by the Chronic Malignancies Working Party of the EBMT
195. Fatal amyloid formation in a patient’s antibody light chain is caused by a single point mutation
196. Author response: Fatal amyloid formation in a patient’s antibody light chain is caused by a single point mutation
197. Prognosis and Staging of AL Amyloidosis
198. Conditioning‐based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991‐2012) on behalf of EBMT CMWP
199. Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017
200. Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.